Novo Nordisk's, opens new tab hugely popular weight-loss drug Wegovy has been approved in China, it said on Tuesday, the world's second-largest economy and the country estimated to hold the highest number of overweight or obese people.
The company will communicate details on pricing and availability when it launches, it told Reuters in a statement. Novo said in March it would initially target Chinese patients willing to pay out-of-pocket for the weekly injectable drug.
The number of overweight adults in China, the world's second most populous country, is projected to reach 540 million by 2030, 2.8 times higher than 2000 levels, a Chinese public health study showed in 2020. Numbers who are obese are seen jumping 7.5 times to 150 million.
